肺動脈性肺高血圧症治療薬の世界市場 2023-2027

当レポートでは、肺動脈性肺高血圧症治療薬の市場規模は、2022年から2027年の間に20億8,007万米ドル、予測期間中のCAGRは6.62%で成長すると予測しています。

当レポートでは、肺動脈性肺高血圧症治療薬市場について、全体的な分析、市場規模と予測、動向、成長促進要因・課題、さらに約25のベンダーを網羅したベンダー分析を行っています。

現在の市場シナリオ、最新の動向と促進要因、市場全体の環境に関する最新の分析を提供しています。市場は、PAHの有病率の増加、老年人口の増加、心血管疾患のリスク要因の増加によって牽引されています。

本調査では、PAHに関する意識の高まりが、今後数年間の肺動脈性肺高血圧症治療薬市場の成長を促進する主要な理由の1つであると特定しています。また、技術的進歩や新製品の発売、pah治療薬の認可の高まりは、市場の大きな需要につながるでしょう。

目次

第1章 エグゼクティブサマリー

• 市場概要

第2章 市場情勢

• 市場エコシステム

第3章 市場規模

• 市場の定義
• 市場別分析
• 市場規模 2022
• 市場の見通し 2022-2027

第4章 市場規模実績

• 肺動脈性肺高血圧症治療薬の世界市場 2017-2021
• 投与経路セグメント分析 2017-2021
• アクションメカニズムセグメント分析 2017-2021
• 地域別分析 2017-2021
• 国別分析 2017-2021

第5章 ファイブフォース分析

• ファイブフォースの要約
• 買い手の交渉力
• 供給企業の交渉力
• 新規参入業者の脅威
• 代替品の脅威
• 競争の脅威
• 市況

第6章 市場セグメンテーション：投与経路別

• 市場セグメント
• 比較：投与経路別
• オーラル：市場規模と予測 2022-2027
• 注射可能：市場規模と予測 2022-2027
• 吸入：市場規模と予測 2022-2027
• 市場機会：投与経路別

第7章 市場セグメンテーションアクションメカニズム別

• 市場セグメント
• 比較アクションメカニズム別
• プロスタサイクリン類似体：市場規模と予測 2022-2027
• エンドセリン受容体拮抗薬（ERA）：市場規模と予測 2022-2027
• ホスホジエステラーゼ（PDE）阻害剤：市場規模と予測 2022-2027
• 可溶性グアニル酸シクラーゼ刺激剤（SGCS）：市場規模と予測 2022-2027
• 市場機会アクションメカニズム別

第8章 顧客情勢

• 顧客情勢の概要

第9章 地域別情勢

• 地域別セグメンテーション
• 地域別比較
• 北米：市場規模と予測 2022-2027
• 欧州：市場規模と予測 2022-2027
• アジア：市場規模と予測 2022-2027
• 世界のその他の地域：市場規模と予測 2022-2027
• 米国：市場規模と予測 2022-2027
• 英国：市場規模と予測 2022-2027
• ドイツ：市場規模と予測 2022-2027
• カナダ：市場規模と予測 2022-2027
• 日本：市場規模と予測 2022-2027
• 市場機会：地域別

第10章 促進要因、課題、および動向

• 市場促進要因
• 市場の課題
• 促進要因と課題の影響
• 市場動向

第11章 ベンダー情勢

• 概要
• ベンダー情勢
• 混乱の状況
• 業界のリスク

第12章 ベンダー分析

• 対象ベンダー
• ベンダーの市場ポジショニング
• Aerami Therapeutics Holdings Inc.
• Asklepion Pharmaceuticals LLC
• AstraZeneca Plc
• Bayer AG
• Daiichi Sankyo Co. Ltd.
• Eiger BioPharmaceuticals Inc.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Johnson and Johnson Services Inc.
• Lupin Ltd.
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• United Therapeutics Corp.

第13章 付録

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market by Geography
• Exhibits5: Executive Summary - Chart on Market Segmentation by Route of Administration
• Exhibits6: Executive Summary - Chart on Market Segmentation by Action Mechanism
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibits18: Historic Market Size - Data Table on Global Pulmonary Arterial Hypertension Drugs Market 2017 - 2021 ($ million)
• Exhibits19: Historic Market Size - Route of Administration Segment 2017 - 2021 ($ million)
• Exhibits20: Historic Market Size - Action Mechanism Segment 2017 - 2021 ($ million)
• Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
• Exhibits23: Five forces analysis - Comparison between 2022 and 2027
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
• Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
• Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
• Exhibits29: Chart on Market condition - Five forces 2022 and 2027
• Exhibits30: Chart on Route of Administration - Market share 2022-2027 (%)
• Exhibits31: Data Table on Route of Administration - Market share 2022-2027 (%)
• Exhibits32: Chart on Comparison by Route of Administration
• Exhibits33: Data Table on Comparison by Route of Administration
• Exhibits34: Chart on Oral - Market size and forecast 2022-2027 ($ million)
• Exhibits35: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
• Exhibits36: Chart on Oral - Year-over-year growth 2022-2027 (%)
• Exhibits37: Data Table on Oral - Year-over-year growth 2022-2027 (%)
• Exhibits38: Chart on Injectable - Market size and forecast 2022-2027 ($ million)
• Exhibits39: Data Table on Injectable - Market size and forecast 2022-2027 ($ million)
• Exhibits40: Chart on Injectable - Year-over-year growth 2022-2027 (%)
• Exhibits41: Data Table on Injectable - Year-over-year growth 2022-2027 (%)
• Exhibits42: Chart on Inhalation - Market size and forecast 2022-2027 ($ million)
• Exhibits43: Data Table on Inhalation - Market size and forecast 2022-2027 ($ million)
• Exhibits44: Chart on Inhalation - Year-over-year growth 2022-2027 (%)
• Exhibits45: Data Table on Inhalation - Year-over-year growth 2022-2027 (%)
• Exhibits46: Market opportunity by Route of Administration ($ million)
• Exhibits47: Data Table on Market opportunity by Route of Administration ($ million)
• Exhibits48: Chart on Action Mechanism - Market share 2022-2027 (%)
• Exhibits49: Data Table on Action Mechanism - Market share 2022-2027 (%)
• Exhibits50: Chart on Comparison by Action Mechanism
• Exhibits51: Data Table on Comparison by Action Mechanism
• Exhibits52: Chart on Prostacyclin analogs - Market size and forecast 2022-2027 ($ million)
• Exhibits53: Data Table on Prostacyclin analogs - Market size and forecast 2022-2027 ($ million)
• Exhibits54: Chart on Prostacyclin analogs - Year-over-year growth 2022-2027 (%)
• Exhibits55: Data Table on Prostacyclin analogs - Year-over-year growth 2022-2027 (%)
• Exhibits56: Chart on Endothelin receptor antagonists (ERAs) - Market size and forecast 2022-2027 ($ million)
• Exhibits57: Data Table on Endothelin receptor antagonists (ERAs) - Market size and forecast 2022-2027 ($ million)
• Exhibits58: Chart on Endothelin receptor antagonists (ERAs) - Year-over-year growth 2022-2027 (%)
• Exhibits59: Data Table on Endothelin receptor antagonists (ERAs) - Year-over-year growth 2022-2027 (%)
• Exhibits60: Chart on Phosphodiesterase (PDE) inhibitors - Market size and forecast 2022-2027 ($ million)
• Exhibits61: Data Table on Phosphodiesterase (PDE) inhibitors - Market size and forecast 2022-2027 ($ million)
• Exhibits62: Chart on Phosphodiesterase (PDE) inhibitors - Year-over-year growth 2022-2027 (%)
• Exhibits63: Data Table on Phosphodiesterase (PDE) inhibitors - Year-over-year growth 2022-2027 (%)
• Exhibits64: Chart on Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2022-2027 ($ million)
• Exhibits65: Data Table on Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2022-2027 ($ million)
• Exhibits66: Chart on Soluble guanylate cyclase stimulators (SGCSs) - Year-over-year growth 2022-2027 (%)
• Exhibits67: Data Table on Soluble guanylate cyclase stimulators (SGCSs) - Year-over-year growth 2022-2027 (%)
• Exhibits68: Market opportunity by Action Mechanism ($ million)
• Exhibits69: Data Table on Market opportunity by Action Mechanism ($ million)
• Exhibits70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits71: Chart on Market share by geography 2022-2027 (%)
• Exhibits72: Data Table on Market share by geography 2022-2027 (%)
• Exhibits73: Chart on Geographic comparison
• Exhibits74: Data Table on Geographic comparison
• Exhibits75: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibits76: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibits77: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibits78: Data Table on North America - Year-over-year growth 2022-2027 (%)
• Exhibits79: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibits80: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibits81: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• Exhibits83: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibits84: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibits85: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• Exhibits87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibits88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibits89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibits91: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibits92: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibits93: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibits94: Data Table on US - Year-over-year growth 2022-2027 (%)
• Exhibits95: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibits96: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibits97: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibits98: Data Table on UK - Year-over-year growth 2022-2027 (%)
• Exhibits99: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibits100: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibits101: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits102: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• Exhibits103: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibits104: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibits105: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibits106: Data Table on Canada - Year-over-year growth 2022-2027 (%)
• Exhibits107: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibits108: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibits109: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibits110: Data Table on Japan - Year-over-year growth 2022-2027 (%)
• Exhibits111: Market opportunity by geography ($ million)
• Exhibits112: Data Tables on Market opportunity by geography ($ million)
• Exhibits113: Impact of drivers and challenges in 2022 and 2027
• Exhibits114: Overview on Criticality of inputs and Factors of differentiation
• Exhibits115: Overview on factors of disruption
• Exhibits116: Impact of key risks on business
• Exhibits117: Vendors covered
• Exhibits118: Matrix on vendor position and classification
• Exhibits119: Aerami Therapeutics Holdings Inc. - Overview
• Exhibits120: Aerami Therapeutics Holdings Inc. - Product / Service
• Exhibits121: Aerami Therapeutics Holdings Inc. - Key offerings
• Exhibits122: Asklepion Pharmaceuticals LLC - Overview
• Exhibits123: Asklepion Pharmaceuticals LLC - Product / Service
• Exhibits124: Asklepion Pharmaceuticals LLC - Key offerings
• Exhibits125: AstraZeneca Plc - Overview
• Exhibits126: AstraZeneca Plc - Product / Service
• Exhibits127: AstraZeneca Plc - Key news
• Exhibits128: AstraZeneca Plc - Key offerings
• Exhibits129: Bayer AG - Overview
• Exhibits130: Bayer AG - Business segments
• Exhibits131: Bayer AG - Key news
• Exhibits132: Bayer AG - Key offerings
• Exhibits133: Bayer AG - Segment focus
• Exhibits134: Daiichi Sankyo Co. Ltd. - Overview
• Exhibits135: Daiichi Sankyo Co. Ltd. - Business segments
• Exhibits136: Daiichi Sankyo Co. Ltd. - Key news
• Exhibits137: Daiichi Sankyo Co. Ltd. - Key offerings
• Exhibits138: Daiichi Sankyo Co. Ltd. - Segment focus
• Exhibits139: Eiger BioPharmaceuticals Inc. - Overview
• Exhibits140: Eiger BioPharmaceuticals Inc. - Product / Service
• Exhibits141: Eiger BioPharmaceuticals Inc. - Key offerings
• Exhibits142: Gilead Sciences Inc. - Overview
• Exhibits143: Gilead Sciences Inc. - Product / Service
• Exhibits144: Gilead Sciences Inc. - Key news
• Exhibits145: Gilead Sciences Inc. - Key offerings
• Exhibits146: GlaxoSmithKline Plc - Overview
• Exhibits147: GlaxoSmithKline Plc - Business segments
• Exhibits148: GlaxoSmithKline Plc - Key news
• Exhibits149: GlaxoSmithKline Plc - Key offerings
• Exhibits150: GlaxoSmithKline Plc - Segment focus
• Exhibits151: Johnson and Johnson Services Inc. - Overview
• Exhibits152: Johnson and Johnson Services Inc. - Business segments
• Exhibits153: Johnson and Johnson Services Inc. - Key news
• Exhibits154: Johnson and Johnson Services Inc. - Key offerings
• Exhibits155: Johnson and Johnson Services Inc. - Segment focus
• Exhibits156: Lupin Ltd. - Overview
• Exhibits157: Lupin Ltd. - Product / Service
• Exhibits158: Lupin Ltd. - Key news
• Exhibits159: Lupin Ltd. - Key offerings
• Exhibits160: Merck and Co. Inc. - Overview
• Exhibits161: Merck and Co. Inc. - Business segments
• Exhibits162: Merck and Co. Inc. - Key news
• Exhibits163: Merck and Co. Inc. - Key offerings
• Exhibits164: Merck and Co. Inc. - Segment focus
• Exhibits165: Novartis AG - Overview
• Exhibits166: Novartis AG - Business segments
• Exhibits167: Novartis AG - Key offerings
• Exhibits168: Novartis AG - Segment focus
• Exhibits169: Pfizer Inc. - Overview
• Exhibits170: Pfizer Inc. - Product / Service
• Exhibits171: Pfizer Inc. - Key news
• Exhibits172: Pfizer Inc. - Key offerings
• Exhibits173: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibits174: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibits175: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibits176: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibits177: Teva Pharmaceutical Industries Ltd. - Segment focus
• Exhibits178: United Therapeutics Corp. - Overview
• Exhibits179: United Therapeutics Corp. - Product / Service
• Exhibits180: United Therapeutics Corp. - Key offerings
• Exhibits181: Inclusions checklist
• Exhibits182: Exclusions checklist
• Exhibits183: Currency conversion rates for US$
• Exhibits184: Research methodology
• Exhibits185: Validation techniques employed for market sizing
• Exhibits186: Information sources
• Exhibits187: List of abbreviations

Technavio has been monitoring the pulmonary arterial hypertension drugs market and is forecast to grow by $2080.07 mn during 2022-2027, accelerating at a CAGR of 6.62% during the forecast period. Our report on the pulmonary arterial hypertension drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of PAH, the growing geriatric population, and increased risk factors for cardiovascular diseases.

Technavio's pulmonary arterial hypertension drugs market is segmented as below:

By Route of Administration

• Oral
• Injectable
• Inhalation

By Action Mechanism

• Prostacyclin analogs
• Endothelin receptor antagonists (ERAs)
• Phosphodiesterase (PDE) inhibitors
• Soluble guanylate cyclase stimulators (SGCSs)

By Geography

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the increasing awareness regarding pah as one of the prime reasons driving the pulmonary arterial hypertension drugs market growth during the next few years. Also, growing technological advancements and new product launches and rising approval of pah drugs will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the pulmonary arterial hypertension drugs market covers the following areas:

• Pulmonary arterial hypertension drugs market sizing
• Pulmonary arterial hypertension drugs market forecast
• Pulmonary arterial hypertension drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pulmonary arterial hypertension drugs market vendors that include Aerami Therapeutics Holdings Inc., Aerovate Therapeutics Inc., Alembic Pharmaceuticals Ltd., Asklepion Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eiger BioPharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Reata Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corp., and Viatris Inc. Also, the pulmonary arterial hypertension drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market by Geography
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Action Mechanism
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2022
• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global Pulmonary Arterial Hypertension Drugs Market 2017 - 2021
• Exhibit 18: Historic Market Size - Data Table on Global Pulmonary Arterial Hypertension Drugs Market 2017 - 2021 ($ million)
• 4.2 Route of Administration Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size - Route of Administration Segment 2017 - 2021 ($ million)
• 4.3 Action Mechanism Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size - Action Mechanism Segment 2017 - 2021 ($ million)
• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Route of Administration

• 6.1 Market segments
• Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)
• 6.2 Comparison by Route of Administration
• Exhibit 32: Chart on Comparison by Route of Administration
• Exhibit 33: Data Table on Comparison by Route of Administration
• 6.3 Oral - Market size and forecast 2022-2027
• Exhibit 34: Chart on Oral - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Oral - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Oral - Year-over-year growth 2022-2027 (%)
• 6.4 Injectable - Market size and forecast 2022-2027
• Exhibit 38: Chart on Injectable - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Injectable - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Injectable - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Injectable - Year-over-year growth 2022-2027 (%)
• 6.5 Inhalation - Market size and forecast 2022-2027
• Exhibit 42: Chart on Inhalation - Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Inhalation - Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Inhalation - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Inhalation - Year-over-year growth 2022-2027 (%)
• 6.6 Market opportunity by Route of Administration
• Exhibit 46: Market opportunity by Route of Administration ($ million)
• Exhibit 47: Data Table on Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Action Mechanism

• 7.1 Market segments
• Exhibit 48: Chart on Action Mechanism - Market share 2022-2027 (%)
• Exhibit 49: Data Table on Action Mechanism - Market share 2022-2027 (%)
• 7.2 Comparison by Action Mechanism
• Exhibit 50: Chart on Comparison by Action Mechanism
• Exhibit 51: Data Table on Comparison by Action Mechanism
• 7.3 Prostacyclin analogs - Market size and forecast 2022-2027
• Exhibit 52: Chart on Prostacyclin analogs - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Data Table on Prostacyclin analogs - Market size and forecast 2022-2027 ($ million)
• Exhibit 54: Chart on Prostacyclin analogs - Year-over-year growth 2022-2027 (%)
• Exhibit 55: Data Table on Prostacyclin analogs - Year-over-year growth 2022-2027 (%)
• 7.4 Endothelin receptor antagonists (ERAs) - Market size and forecast 2022-2027
• Exhibit 56: Chart on Endothelin receptor antagonists (ERAs) - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Data Table on Endothelin receptor antagonists (ERAs) - Market size and forecast 2022-2027 ($ million)
• Exhibit 58: Chart on Endothelin receptor antagonists (ERAs) - Year-over-year growth 2022-2027 (%)
• Exhibit 59: Data Table on Endothelin receptor antagonists (ERAs) - Year-over-year growth 2022-2027 (%)
• 7.5 Phosphodiesterase (PDE) inhibitors - Market size and forecast 2022-2027
• Exhibit 60: Chart on Phosphodiesterase (PDE) inhibitors - Market size and forecast 2022-2027 ($ million)
• Exhibit 61: Data Table on Phosphodiesterase (PDE) inhibitors - Market size and forecast 2022-2027 ($ million)
• Exhibit 62: Chart on Phosphodiesterase (PDE) inhibitors - Year-over-year growth 2022-2027 (%)
• Exhibit 63: Data Table on Phosphodiesterase (PDE) inhibitors - Year-over-year growth 2022-2027 (%)
• 7.6 Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2022-2027
• Exhibit 64: Chart on Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2022-2027 ($ million)
• Exhibit 65: Data Table on Soluble guanylate cyclase stimulators (SGCSs) - Market size and forecast 2022-2027 ($ million)
• Exhibit 66: Chart on Soluble guanylate cyclase stimulators (SGCSs) - Year-over-year growth 2022-2027 (%)
• Exhibit 67: Data Table on Soluble guanylate cyclase stimulators (SGCSs) - Year-over-year growth 2022-2027 (%)
• 7.7 Market opportunity by Action Mechanism
• Exhibit 68: Market opportunity by Action Mechanism ($ million)
• Exhibit 69: Data Table on Market opportunity by Action Mechanism ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 71: Chart on Market share by geography 2022-2027 (%)
• Exhibit 72: Data Table on Market share by geography 2022-2027 (%)
• 9.2 Geographic comparison
• Exhibit 73: Chart on Geographic comparison
• Exhibit 74: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%)
• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• 9.7 US - Market size and forecast 2022-2027
• Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%)
• 9.8 UK - Market size and forecast 2022-2027
• Exhibit 95: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 96: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 97: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on UK - Year-over-year growth 2022-2027 (%)
• 9.9 Germany - Market size and forecast 2022-2027
• Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%)
• 9.10 Canada - Market size and forecast 2022-2027
• Exhibit 103: Chart on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 104: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
• Exhibit 105: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 106: Data Table on Canada - Year-over-year growth 2022-2027 (%)
• 9.11 Japan - Market size and forecast 2022-2027
• Exhibit 107: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 108: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 109: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 110: Data Table on Japan - Year-over-year growth 2022-2027 (%)
• 9.12 Market opportunity by geography
• Exhibit 111: Market opportunity by geography ($ million)
• Exhibit 112: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 113: Impact of drivers and challenges in 2022 and 2027
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 115: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 116: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 117: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 118: Matrix on vendor position and classification
• 12.3 Aerami Therapeutics Holdings Inc.
• Exhibit 119: Aerami Therapeutics Holdings Inc. - Overview
• Exhibit 120: Aerami Therapeutics Holdings Inc. - Product / Service
• Exhibit 121: Aerami Therapeutics Holdings Inc. - Key offerings
• 12.4 Asklepion Pharmaceuticals LLC
• Exhibit 122: Asklepion Pharmaceuticals LLC - Overview
• Exhibit 123: Asklepion Pharmaceuticals LLC - Product / Service
• Exhibit 124: Asklepion Pharmaceuticals LLC - Key offerings
• 12.5 AstraZeneca Plc
• Exhibit 125: AstraZeneca Plc - Overview
• Exhibit 126: AstraZeneca Plc - Product / Service
• Exhibit 127: AstraZeneca Plc - Key news
• Exhibit 128: AstraZeneca Plc - Key offerings
• 12.6 Bayer AG
• Exhibit 129: Bayer AG - Overview
• Exhibit 130: Bayer AG - Business segments
• Exhibit 131: Bayer AG - Key news
• Exhibit 132: Bayer AG - Key offerings
• Exhibit 133: Bayer AG - Segment focus
• 12.7 Daiichi Sankyo Co. Ltd.
• Exhibit 134: Daiichi Sankyo Co. Ltd. - Overview
• Exhibit 135: Daiichi Sankyo Co. Ltd. - Business segments
• Exhibit 136: Daiichi Sankyo Co. Ltd. - Key news
• Exhibit 137: Daiichi Sankyo Co. Ltd. - Key offerings
• Exhibit 138: Daiichi Sankyo Co. Ltd. - Segment focus
• 12.8 Eiger BioPharmaceuticals Inc.
• Exhibit 139: Eiger BioPharmaceuticals Inc. - Overview
• Exhibit 140: Eiger BioPharmaceuticals Inc. - Product / Service
• Exhibit 141: Eiger BioPharmaceuticals Inc. - Key offerings
• 12.9 Gilead Sciences Inc.
• Exhibit 142: Gilead Sciences Inc. - Overview
• Exhibit 143: Gilead Sciences Inc. - Product / Service
• Exhibit 144: Gilead Sciences Inc. - Key news
• Exhibit 145: Gilead Sciences Inc. - Key offerings
• 12.10 GlaxoSmithKline Plc
• Exhibit 146: GlaxoSmithKline Plc - Overview
• Exhibit 147: GlaxoSmithKline Plc - Business segments
• Exhibit 148: GlaxoSmithKline Plc - Key news
• Exhibit 149: GlaxoSmithKline Plc - Key offerings
• Exhibit 150: GlaxoSmithKline Plc - Segment focus
• 12.11 Johnson and Johnson Services Inc.
• Exhibit 151: Johnson and Johnson Services Inc. - Overview
• Exhibit 152: Johnson and Johnson Services Inc. - Business segments
• Exhibit 153: Johnson and Johnson Services Inc. - Key news
• Exhibit 154: Johnson and Johnson Services Inc. - Key offerings
• Exhibit 155: Johnson and Johnson Services Inc. - Segment focus
• 12.12 Lupin Ltd.
• Exhibit 156: Lupin Ltd. - Overview
• Exhibit 157: Lupin Ltd. - Product / Service
• Exhibit 158: Lupin Ltd. - Key news
• Exhibit 159: Lupin Ltd. - Key offerings
• 12.13 Merck and Co. Inc.
• Exhibit 160: Merck and Co. Inc. - Overview
• Exhibit 161: Merck and Co. Inc. - Business segments
• Exhibit 162: Merck and Co. Inc. - Key news
• Exhibit 163: Merck and Co. Inc. - Key offerings
• Exhibit 164: Merck and Co. Inc. - Segment focus
• 12.14 Novartis AG
• Exhibit 165: Novartis AG - Overview
• Exhibit 166: Novartis AG - Business segments
• Exhibit 167: Novartis AG - Key offerings
• Exhibit 168: Novartis AG - Segment focus
• 12.15 Pfizer Inc.
• Exhibit 169: Pfizer Inc. - Overview
• Exhibit 170: Pfizer Inc. - Product / Service
• Exhibit 171: Pfizer Inc. - Key news
• Exhibit 172: Pfizer Inc. - Key offerings
• 12.16 Teva Pharmaceutical Industries Ltd.
• Exhibit 173: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 174: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 175: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 176: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 177: Teva Pharmaceutical Industries Ltd. - Segment focus
• 12.17 United Therapeutics Corp.
• Exhibit 178: United Therapeutics Corp. - Overview
• Exhibit 179: United Therapeutics Corp. - Product / Service
• Exhibit 180: United Therapeutics Corp. - Key offerings

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 181: Inclusions checklist
• Exhibit 182: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 183: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 184: Research methodology
• Exhibit 185: Validation techniques employed for market sizing
• Exhibit 186: Information sources
• 13.5 List of abbreviations
• Exhibit 187: List of abbreviations